title: A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
authors.forename: Melina
authors.initials: M
authors.lastname: Verso
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Agnelli
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
authors.forename: Giampietro
authors.initials: G
authors.lastname: Gasparini
authors.forename: Roberto
authors.initials: R
authors.lastname: LaBianca
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D016001:Confidence Intervals; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006305:Health Status Indicators; D006801:Humans; D017762:Nadroparin / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D011237:Predictive Value of Tests; D012306:Risk; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control
chemical_list: D000970:Antineoplastic Agents; D005343:Fibrinolytic Agents; D017762:Nadroparin